NCT07070388 is a NA clinical trial of end-effector robotic training in Multiple Sclerosis, sponsored by Michael Holmes.

Who is sponsoring NCT07070388?

NCT07070388 is sponsored by Michael Holmes.

What drugs are being tested in NCT07070388?

Interventions in NCT07070388: end-effector robotic training.

What condition does NCT07070388 study?

NCT07070388 studies Multiple Sclerosis.

Is NCT07070388 still recruiting?

NCT07070388 is currently completed. Last updated 17 July 2025.

Last reviewed 2025-07-17 · How we verify

NCT07070388

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Robotic -Assisted Rehabilitation for Multiple Sclerosis: An Adaptive Approach for Individualized Therapy

Completed NA Last updated 17 July 2025

What this trial tests

NA trial testing end-effector robotic training in Multiple Sclerosis in 9 participants. Completed in 27 June 2025.

Timeline

1 January 2023

Primary endpoint
31 August 2023

27 June 2025

Quick facts

Lead sponsor	Michael Holmes
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	9
Start date	1 January 2023
Primary completion	31 August 2023
Estimated completion	27 June 2025
Sites	1 location across Canada

Drugs / interventions tested

end-effector robotic training

Conditions studied

Multiple Sclerosis — all drugs for Multiple Sclerosis →

Sponsor

Michael Holmes

Who can join

Adults 18 to 75, any sex, with Multiple Sclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Therefore, the purpose of this study was to evaluate four-weeks of an upper limb robotic intervention for persons with Multiple Sclerosis. Participants completed a resistive and adaptive robotic training intervention whereby participants trained three times weekly for four consecutive weeks.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Multiple Sclerosis

Currently open trials in the same condition.

NCT07507084 — The Effect of Internal- or External-Focused Exercise Training, Administered in Conjunction With a Cognitive Task, on Wal · NA · recruiting
NCT07524231 — Evaluation of the Effects of Laughter Yoga · NA · recruiting
NCT07489794 — URINARY INCONTINENCE AND PELVIC FLOOR MUSCLE ACTIVITY IN MULTIPLE SCLEROSIS · recruiting
NCT07236684 — Identification of Factors Related to UI in Patients With MS and EMG Assessment of PFM Activity · recruiting
NCT07500727 — Skeletal Muscle Aging and Responsiveness in Aged People With MS · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07070388 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Michael Holmes
Last refreshed: 17 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07070388.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing